2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Pathogenesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Diseases, Immunology, Autoimmune Disorders, GVHD, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

2369 Baseline gut microbiome profiles stratify CAR-T persistence and clinical outcomes in B-cell acute lymphoblastic leukemia

Tiantian Wang, PhD, Haoren Wang2, Wenbing Liu3, Shaowei Qiu, MD4, Guangji Zhang5, Xiaoyuan Gong, MD6, Yuntao Liu7, Qiuyun Fang8, Kaiqi Liu9, Dong Lin10, Chunlin Zhou11, Benfa Gong, MMSc12, Shuning Wei13, Yan Li14, Shouyun Li15, Ying Wang, MD16, Yan Hui17, Bingcheng LIU, MD18, Yingchang Mi, MD19, Hui Wei, MD, PhD20, Ying Wang, MD, PhD21, Runxia Gu, MD22, Jianxiang Wang Sr, MD, PhD23
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
7 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
8 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
9 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
10 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
11 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
12 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
13 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
14 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
15 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
16 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
17 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
18 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
19 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
20 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
21 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
22 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
23 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China

Objectives

Chimeric antigen receptor T (CAR-T) cell therapy efficacy is closely linked to the in vivo expansion and long-term persistence of infused CAR-T cells, yet the host factors that associated with CAR-T cell fate remain incompletely understood. The gut microbiome has emerged as a critical regulator of systemic immunity, with microbial metabolites and immune-modulatory pathways shaping T-cell activation, differentiation, and functional persistence. However, whether and how the gut microbiota influences CAR-T cell persistence remains largely unexplored, partly due to the substantial confounding effects imposed by tumor burden, disease status, and treatment-related factors in previous studies.

Methods

To address this question, we analyzed 35 baseline stool samples from patients with B-cell acute lymphoblastic leukemia (B-ALL) enrolled in a prospective front-line anti-CD19 CAR-T clinical trial. This front-line setting enabled us to minimize the confounding effects of tumor burden and disease progression, allowing a more precise evaluation of the contribution of baseline host factors. Stool samples were collected at apheresis day and subjected to shotgun metagenomic sequencing, while CAR-T expansion kinetics, peripheral blood CAR-T levels, T-cell subsets, cytokines, and clinical outcomes were longitudinally monitored. We integrated gut metagenomic profiles with CAR-T kinetics and clinical data using unsupervised clustering, Linear discriminant analysis (LDA) of effect size (LEfSe) analysis, and a generalized linear model–based risk score to evaluate the association between baseline microbial features, CAR-T persistence, and clinical outcomes.

Results

Baseline gut microbiome composition stratified patients into distinct CAR-T persistence phenotypes. By hierarchical clustering of 668 family-level abundances on apheresis day, three clusters (C1, C2, and C3) were identified. C1 was dominated by Bacteroidaceae (LDA score = 5.30, FDR = 0.006), had the lowest alpha diversity (Shannon index, median 1.09 vs. 1.54 and 1.57 in C2 and C3, Wilcoxon p < 0.001), and showed superior CAR-T persistence. Conversely, C2, enriched in Oscillospiraceae (LDA score = 4.76, FDR = 0.02), exhibited poor CAR-T persistence, with undetectable peripheral CAR-T levels in all 12 patients at month 2 and/or month 3, and relapse was observed in 3 of 10 non-transplanted patients versus 1 of 17 in C1. C3 was enriched in Enterobacteriaceae (LDA score = 4.96, FDR = 0.03) and had the lowest CRS incidence (2/6, 33%) compared with that of C1 (13/17, 76%) and C2 (8/12, 67%).

To explore the potential mechanisms linking gut microbiota and CAR-T persistence, we compared immune profiles across microbiome-defined clusters. At baseline, patients in C2 exhibited significantly higher frequencies of regulatory T cells (Tregs) (median 3.3% vs. 1.81% and 2.99% in C1 and C3, Wilcoxon p = 0.006). Following CAR-T infusion, C2 patients displayed transient elevation of IL-2 and IL-12p70 levels at day 14 (IL-2: median 1.43 vs. 0.89 and 0.95 pg/mL in C1 and C3, Wilcoxon p = 0.01; IL-12p70: median 2.41 vs. 1.66 and 1.55 pg/mL in C1 and C3, Wilcoxon p = 0.01), but subsequently showed reduced central memory CD8? T-cell proportions at day 28 (median 0.61% vs. 1.83% in C1, Wilcoxon p = 0.02), which be reported associated with long-lived CAR-T populations.

To translate these findings into an early prediction strategy, we developed a baseline metagenomic risk score (MRS) using the five most discriminatory bacterial families (Bacteroidaceae, Enterobacteriaceae, Oscillospiraceae, Eubacteriaceae and Pasteurellaceae). The five-family MRS accurately identified patients with the favorable C1 microbiome phenotype (AUC = 0.96). Using a predefined cutoff, low-risk patients showed a numerically higher 12-month relapse-free survival than high-risk patients (94.4% vs. 68.3%, log-rank P = 0.06).

Conclusions

Baseline gut flora on apheresis day predicts CAR-T persistence and relapse in B-ALL, with Bacteroidaceae-dominant C1 linked to better outcomes and Oscillospiraceae-enriched C2 to worse outcomes. The MRS, though modest, offers a non-invasive early biomarker. Microbiota-directed interventions (e.g. fecal microbiota transplantation) before CAR-T may enhance persistence, but validation in larger cohorts is needed.

Tiantian Wang, PhD: No relevant conflicts of interest to declare.